Disposition of 4460 shares by Salzmann Peter of Immunovant at 29.56 subject to Rule 16b-3
| IMVT Stock | USD 20.08 0.30 1.52% |
Slightly above 50% of Immunovant's private investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Immunovant suggests that some traders are interested. Immunovant's investing sentiment can be driven by a variety of factors including economic data, Immunovant's earnings reports, geopolitical events, and overall market trends.
Immunovant |
Filed transaction by Immunovant Director, Officer: Chief Executive Officer. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Read at macroaxis.com
Immunovant Fundamental Analysis
We analyze Immunovant's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Immunovant using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Immunovant based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Cash Per Share
Cash Per Share Comparative Analysis
Immunovant is currently under evaluation in cash per share category among its peers. Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Immunovant Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Immunovant stock to make a market-neutral strategy. Peer analysis of Immunovant could also be used in its relative valuation, which is a method of valuing Immunovant by comparing valuation metrics with similar companies.
Peers
Immunovant Related Equities
| MDGL | Madrigal Pharmaceuticals | 14.99 | ||||
| ARQT | Arcutis Biotherapeutics | 8.36 | ||||
| AMLX | Amylyx Pharmaceuticals | 4.58 | ||||
| PTGX | Protagonist Therapeutics | 3.02 | ||||
| AKRO | Akero Therapeutics | 0.25 | ||||
| STOK | Stoke Therapeutics | 0.24 | ||||
| BPMC | Blueprint Medicines | 0.15 | ||||
| ETNB | 89bio | 0.11 | ||||
| ABUS | Arbutus Biopharma | 0.29 | ||||
| LEGN | Legend Biotech | 1.30 | ||||
| PLRX | Pliant Therapeutics | 1.58 | ||||
| APLS | Apellis Pharmaceuticals | 2.12 | ||||
| ACLX | Arcellx | 3.81 | ||||
| DAWN | Day One | 16.50 |
Additional Tools for Immunovant Stock Analysis
When running Immunovant's price analysis, check to measure Immunovant's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunovant is operating at the current time. Most of Immunovant's value examination focuses on studying past and present price action to predict the probability of Immunovant's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunovant's price. Additionally, you may evaluate how the addition of Immunovant to your portfolios can decrease your overall portfolio volatility.